Oncolytics treats first patient in Phase Ib of Reolysin for MM

Oncolytics Biotech Inc. (TSX:ONC; OTCQX:ONCYF) said the first patient has been dosed in the Phase Ib MUK eleven trial of Reolysin pelareorep in combination with Revlimid lenalidomide or Imnovid pomalidomide from Celgene Corp. (NASDAQ:CELG) as a rescue treatment in relapsing or refractory multiple myeloma (MM) patients who are progressing despite treatment with 1 of those immunomodulatory agents (IMiDs).

The open-label, dose-escalation, U.K. trial is evaluating IV Reolysin on days 1, 8, 15 and 22 of each 28-day cycle at a starting dose of 3x10¹⁰ 50% tissue culture infective dose (TCID50) in about 44 patients. The primary endpoints are dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD). Secondary endpoints include safety, response rate, maximum response rate within 6 cycles of therapy, time to maximum response, progression-free survival (PFS) and overall survival (OS)...